新诊断2型糖尿病患者胰岛素泵强化治疗前后动态血糖变化

目的探讨新诊断2型糖尿病(T2DM)患者经胰岛素泵(CSII)强化治疗前后动态血糖变化。方法20例新诊断T2DM患者在采用胰岛素泵强化治疗前后分别运用动态血糖监测系统(CGMS)连续3d监测其血糖变化。结果本组患者经2周强化治疗后,能迅速获得理想血糖控制。20例患者治疗前后24h总体血糖达标(餐后2h内小于10mmol/L,其余时间段血糖小于7.0mmol/L)时间分别为(7.5±3.1)h与(14.9±2.3)h,24h平均血糖值为(10.3±2.1)mmol/L与(6.4±1.5)mmol/L,血糖最高值明显下降为(17.5±2.5)mmol/L与(10.3±1.8)mmol/L,上述各参数与治疗前后三餐餐后血糖变化均有明显差异(均p<0.01)。结论新诊断2型糖尿病患者经胰岛素泵强化治疗后,不仅平均血糖明显下降,而且24h总体血糖达标时间明显延长,血糖漂移幅度明显降低。     

笔式诺和灵30R治疗Ⅱ型糖尿病的疗效观察

目的 观察笔式诺和灵30R治疗口服磺脲类药物继发性失效的Ⅱ型糖尿病患者的临床疗效及安全性,血糖控制后胰岛素抵抗情况。方法 对43例Ⅱ型糖尿病口服磺脲类药物继发性失效的患者在控制饮食及运动治疗的基础上加用笔式诺和灵30R皮下注射,每日2次,控制达标后再治疗3周,分别查治疗前后的空腹血糖、餐后血糖、C肽、血脂、肿瘤坏死因子-α。结果 本治疗组患者的空腹血糖、餐后血糖在治疗后显著下降(P<0.001),糖化血红蛋白由9.87±1.06％下降到7.88±2.03％(P<0.01)。治疗后的肿瘤坏死因子-α较治疗前有明显下降(P<0.01)。但治疗前后C肽及血脂无明显上升。结论 提示笔式诺和灵30R可有效控制口服磺脲类药物继发性失效的Ⅱ型糖尿病患者的血糖,通过降低肿瘤坏死因子-α,可改善胰岛素抵抗,且对C肽及血脂无明显影响。     

2型糖尿病并发冠心病患者干预效果评价

目的研究社区综合干预在改善2型糖尿病并发冠心病患者血糖、血脂水平及提高患者生命质量中的作用。方法对158例2型糖尿病并发冠心病患者随机分为2组,其中综合干预组87例,对照组71例。在2组原药物及临床干预不变且差异无统计学意义的前提下,对综合干预组进行定点、定时监测,同时进行家庭随访,并与对照组进行前瞻性的对照研究。结果入组前患者空腹血糖（8.45±2.97）mmol/L,总胆固醇（6.38±1.25）mmol/L,甘油三酯（1.86±0.86）mmol/L,高密度脂蛋白胆固醇（1.38±0.81）mmol/L,低密度脂蛋白胆固醇（4.02±1.39）mmol/L。综合干预1年后,患者空腹血糖（7.18±2.06）mmol/L,总胆固醇（5.27±0.98）mmol/L,甘油三酯（1.40±0.19）mmol/L,高密度脂蛋白胆固醇（2.01±0.65）mmol/L,低密度脂蛋白胆固醇（1.61±0.95）mmol/L,干预前后比较,差异有统计学意义（P〈0.05）,与对照组比较,差异有统计学意义（P〈0.05）。1年后综合干预组的致残率和病死率分别为0.116%,明显低于对照组的7.14%,5.71%,2组比较差异有统计学意义（P〈0.001）;综合干预组1年后患者的生命质量、依从性及生活满意度明显提高,且与对照组比较,差异有统计学意义（P〈0.01）。结论对2型糖尿病并发冠心病患者进行综合干预有改善血糖、血脂及提高生命质量的作用,可成为治疗2型糖尿病及防治2型糖尿病并发冠心病的医学新模式。     

明日叶查尔酮对2型糖尿病大鼠肝脏和骨骼肌葡萄糖转运体表达的影响

目的研究明日叶查尔酮对2型糖尿病大鼠肝脏葡萄糖转运体2(Glut2)和骨骼肌葡萄糖转运体4(Glut4)蛋白表达的影响。方法制造2型糖尿病大鼠模型,随机分成高、中、低剂量组和糖尿病对照组,分别每日灌胃给予30、10、5和0mg/kg BW明日叶查尔酮。各组以高脂饲料喂养4周后,用葡萄糖氧化酶法检测空腹血糖;放射免疫法检测血清胰岛素含量;免疫组化法检测葡萄糖转运体蛋白表达水平。结果经图像分析,高剂量组肝脏和骨骼肌葡萄糖转运体蛋白表达平均光密度值分别为(0.036±0.0030)和(0.063±0.0139),均较糖尿病对照组显著升高(P<0.05)。高剂量组空腹血糖和胰岛素水平分别为(12.3±1.64)mmol/L和(25.65±3.34)μIU/ml,均较糖尿病对照组显著性降低(P<0.05)。结论明日叶查尔酮可上调2型糖尿病大鼠肝脏葡萄糖转运体2和骨骼肌葡萄糖转运体4蛋白表达水平,降低空腹血糖和胰岛素水平,改善糖尿病胰岛素抵抗状况。     

Ⅱ型糖尿病病人血管病变相关因素分析

目的:探讨影响Ⅱ型糖尿病病人血管病变的危险因素。方法:对Ⅱ型糖尿病病人115例的临床资料进行回顾分析,115例分为有血管病变组55例和无血管病变组60例,抽血检查空腹血糖、糖化血红蛋白A_(1C) 、血脂等指标,并与对照组健康人60名的指标比较,对影响Ⅱ型糖尿病病人血管病变的众多因素进行回归分析。结果:糖尿病有血管病变组的空腹血糖、甘油三酯、LDL—C分别为(11.4±5.5)、(4.2±2.2)、(3.7±1.4)mmol/L;无血管病变组相应为(9.5±3.8)、(3.1±1.5)、(2.5±1.1)mmol/L,两组的差异有统计学意义(P<0.05)。Ⅱ型糖尿病病人血管病变的危险因素依次为餐后2小时血糖、空腹血糖,LDL—C、甘油三酯。结论:糖尿病病人的血管病变与血脂、血糖水平有关,控制血糖和血脂对防止糖尿病的血管并发症有重要意义。     

2型糖尿病下肢血管病变发生率及危险因素分析

目的了解2型糖尿病下肢血管病变(PVD)发生率,分析PVD的相关危险因素。方法收集住院的2型糖尿病患者145例进行回顾性分析。结果多普勒超声检查提示有下肢血管病变者占72.41%。2型糖尿病PVD组年龄(66.68±9.87)岁与无PVD组(50.83±12.29)岁相比,差别有统计学意义(P<0.01),PVD组病程(8.63±6.48)a、总胆固醇(4.82±1.18)mmol/L]、低密度脂蛋白胆固醇(2.79±1.01)mmol/L,患高血压比例(74/105)也明显高于无PVD组(P<0.05)。Logistic回归分析结果表明,年龄、性别、病程、总胆固醇是PVD的独立危险因素(OR=1.151,0.098,1.142,2.021)。结论2型糖尿病下肢血管病变发生率高,年龄、性别、病程、血脂是2型糖尿病患者下肢血管病变的危险因素。     

综合护理干预在糖尿病患者中的护理效果探析

目的:集中探讨综合护理干预在糖尿病患者中的护理效果探析.方法:纳入2016年4月-2017年4月因2型糖尿病于我院内分泌科进行治疗的的患者30例,对其进行为期12周的综合护理干预.采用自身对照的方式,对于综合护理干预前后患者的空腹血糖、餐后2小时血糖和糖化血红蛋白三项指标进行比较.结果:干预前后患者空腹血糖分别为(8.81±1.33)mmol/L、(7.51±1.42)mmol/L,餐后2小时血糖分别为(12.36±1.67)mmol/L、(10.97±1.60)mmol/L,糖化血红蛋白分比为(9.61±2.01)％、(7.62±1.96)％.结论:综上所述,综合护理干预对于糖尿病患者病情的控制具有积极的意义,可有效的管理血糖,因此可在临床护理工作中推广使用.     

初诊2型糖尿病短期胰岛素强化治疗观察

目的观察短期胰岛素强化治疗对初诊2型糖尿病产生长期控制的特点。方法对空腹血糖>11.1mmol/L的18例初诊2型糖尿病患者进行为期4w的强化胰岛素治疗,分析比较治疗前后血糖、果糖胺及胰岛素水平的情况。结果空腹血糖从(13.9±0.9)mmol/L降至(6.8±0.6)mmol/L,且这种改善能够维持1年,在1年内7例患者单用饮食控制及运动可以维持良好的血糖控制,11例患者需要口服降糖药治疗,不需使用降糖药组患者其特点是在治疗中需要较少胰岛素即可达到正常血糖水平。结论对伴有明显高血糖的初诊2型糖尿病患者,短期胰岛素强化治疗能成功为今后的良好血糖控制奠定基础,胰岛素治疗达到正常血糖的胰岛素使用量可以预测哪些患者单用饮食控制就能获得良好的血糖控制。     

短期胰岛素泵治疗对2型糖尿病患者的影响

目的探讨短期胰岛素泵治疗对改善2型糖尿病患者的胰岛β细胞功能和血糖控制的影响。方法采用自身前后对照,观察33例新诊断2型糖尿病患者接受2w短期胰岛素泵治疗前后胰岛β细胞对血糖刺激的胰岛素第一时相分泌的变化,探讨胰岛β细胞功能及其影响因素和随访短期胰岛素泵治疗对(不采用任何降糖药物)长期血糖控制的影响。结果治疗2w后,治疗前后静脉葡萄糖试验中胰岛素曲线下面积、胰岛峰值、胰岛素峰值差值、胰岛素与血糖总量比值、胰岛素与血糖增量比值及HomaB指数明显升高;HomaA指数明显下降。治疗前后胰岛素峰值呈正相关。有23例患者仅采用饮食控制,平均随访6个月时糖化血红蛋白为(5·85%±0·61)%,空腹血糖为(6·1±1·2)mmol/L,OGTT2h血糖为(7·8±2·5)mmol/L,空腹胰岛素为(10±5)μU/ml,OGTT2h胰岛素为(20±5)μU/ml。结论短期胰岛素泵治疗可以显著恢复代表胰岛β细胞功能的血糖刺激的胰岛素第一时相分泌,使患者的糖尿病回到2型糖尿病自然病程的更早期阶段,部分患者不用任何药物,仅通过饮食控制就可获得良好的血糖水平。     

检测2型糖尿病患者C-反应蛋白的临床意义分析

目的探讨C-反应蛋白水平的变化在2型糖尿病患者中的临床意义。方法 2011年10月—2012年4月用免疫比浊法和己糖激酶法分别检测118例2型糖尿病患者和55名正常健康体检者的血清C-反应蛋白和空腹血糖水平,同时用Sysmex XT-1800i全自动五分类血细胞分析仪检测白细胞水平,并对各组检测结果进行对比分析。结果空腹血糖、C-反应蛋白和白细胞计数水平观察组分别为(8.50±1.18)mmol/L、(5.92±1.85)mg/L、(7.28±1.25)×109/L;对照组分别为:(4.95±0.54)mmol/L、(1.31±0.47)mg/L、(5.46±0.91)×109/L。两组比较差异均有统计学意义(均P﹤0.05)。结论 C-反应蛋白是发展为2型糖尿病的重要预测因子,可作为2型糖尿病的早期协助诊断指标之一,其与白细胞联合检测对2型糖尿病患者治疗效果的监测具有重要的临床意义。     

Glycemia influences on glucose metabolism in sepsis during hyperinsulinemic clamp

BACKGROUND: We investigated glucose metabolism in septic patients during hyperglycemic clamps and compared the different levels of insulinemia and glycemia. METHODS: In 10 non-diabetic stable septic patients on mechanical ventilation with baseline glycemia >6 mmol/L and continuous insulin infusion, 3 steps of hyperinsulinemic clamp were performed after 8 hours without caloric intake. In step 1, the targets were insulinemia of 250 mIU/L and glycemia of 5 mmol/L; in step 2, insulinemia of 250 mIU/L and glycemia of 10 mmol/L; in step 3, insulinemia of 1250 mIU/L and glycemia of 5 mmol/L. Glucose uptake was calculated as the amount of glucose per time needed to maintain the target level of glycemia. Glucose oxidation was calculated from indirect calorimetry and urinary nitrogen losses. Values are provided as means +/- SD. A two-way analysis of variance and Scheffe's method were used for statistical analysis and p < .05 was considered significant. RESULTS: At step 1, glucose uptake was lower than at step 2 (3.8 +/- 2.48 mg/kg/min and 7.9 +/- 3.45 mg/kg/min, respectively; p < .001). Glucose oxidation was also lower at step 1 (2.6 +/- 0.98 and 4.2 +/- 1.85 mg/kg/min, respectively; p < .01). Glucose storage was low at step 1 (0.7 +/- 1.39) and increased at step 2 (3.5 +/- 2.18; p < .05). In step 3, glucose uptake was 7.0 +/- 2.1, oxidation was 3.6 +/- 1.37, and storage was 2.9 +/- 2.79. There was no significant difference in all these parameters between steps 2 and 3. Energy expenditure between steps 1, 2 and 3 did not change (2294 + 307.42, 2334 + 341.53, and 2342 + 426.67 kcal/day, respectively). Alanine in plasma dropped significantly (p < .05): 10 mmol/L (311 +/- 55.88 mmol/L) at glycemia compared with 5 mmol/L (390 +/- 76 micromol/L) at insulinemia 250 mIU/L. It did not differ significantly from the values obtained at glycemia 5 mmol/L and insulinemia 1250 mIU/L (348 +/- 70.68 mmol/L). Even if the level of cytokines in sepsis was higher, there was no correlation between the insulin level in plasma (250 and 1250 mIU/L), glycemia (5 and 10 mmol/L) and cytokine level (IL-1beta, IL-2, IL-6, IL-8 and TNFalpha). CONCLUSION: At insulinemia 250 mIU/L, a glucose level of 10 mmol/L seems to increase glucose uptake, oxidation, and storage compared with glycemia 5 mmol/L. This glucose uptake and oxidation at glycemia 10 mmol/L is comparable with the effect of extremely high insulinemia (1250 mIU/L) clamped at glycemia 5 mmol/L. A higher level of blood glucose or a high level of insulinemia significantly increases glucose uptake but not energy expenditure.     

平顶山儿童血脂谱水平及相关因素分析

目的了解平顶山儿童血脂谱水平,为心血管疾病的早期预防提供理论依据。方法对平顶山市258名儿童少年进行体格检查及血脂谱水平测定。结果TC、TG、HDL-C、LDL-C的水平分别为(3.51±0.77)、(0.96±0.32)、(1.15±0.24)、(1.76±0.62)(单位均为mmol/L);肥胖儿童的TG水平高于体重正常儿童(P<0.01),HDL-C水平低于体重正常儿童(P<0.05);腰臀围比(WHR)与TG水平呈正相关(r=0.216,P<0.01),收缩压与HDL-C水平呈负相关,r=-0.284。结论检测结果可作为平顶山儿童正常血脂谱水平参考值;肥胖,腰臀围比大、血压偏高可作为筛查血脂异常高危儿童的指标。     

Improved safety with intravenous insulin therapy for critically ill patients with renal failure

ObjectiveThe aim of this study was to evaluate the safety and efficacy of a new intravenous (IV) regular human insulin infusion (RHI) algorithm for glycemic control in critically ill patients with renal failure.MethodsAdult trauma patients with renal failure who received a new RHI algorithm were compared with those who received the discontinued RHI algorithm (historical control). Target blood glucose (BG) concentration was 70 to 149 mg/dL (3.9–8.3 mmol/L). Patients were evaluated for 7 d while receiving the RHI infusion and continuous enteral or parenteral nutrition.ResultsMean BG was higher for the new RHI algorithm group (n = 25) compared with control (n = 21): 145 ± 10 mg/dL or 8.1 ± 0.6 mmol/L versus 133 ± 14 mg/dL or 7.4 ± 0.8 mmol/L (P = 0.001). The new RHI algorithm resulted in less time within the target BG range (11.9 ± 2.5 h/d versus 16.1 ± 3.3 h/d; P = 0.001); however, BGs were within 70 to 179 mg/dL (or 3.9–10 mmol/L) for 16.3 ± 2.6 h/d. The proportion of patients who experienced an episode of moderate hypoglycemia (BG 40–60 mg/dL or 2.2–3.3 mmol/L) or severe hypoglycemia (BG < 40 mg/dL or 2.2 mmol/L) was decreased (32% versus 76%; P = 0.001) and eliminated (0% versus 29%, P = 0.006), respectively.ConclusionsThe new RHI algorithm improved patient safety by decreasing the prevalence of moderate hypoglycemia and eliminating severe hypoglycemia. The duration of glycemic control within the target BG range was decreased, but acceptable within a higher target BG ceiling.     

阿托伐他汀治疗高脂血症的临床观察

目的观察阿托伐他汀治疗高脂血症的临床效果和安全性。方法选择80例总胆固醇(TC)≥6.5mmol/L或甘油三酯(TC)≥1.7mmol/L或高密度脂蛋白胆固醇(HDL-C)≤1.3mmol/L患者给予阿托伐他汀20mg/d,晚间顿服,均治疗12周,12周后分别测定血脂四项,血常规、肝、肾功能,谷丙转氨酶(ALT),肌酸磷酸激酶(CK)等。结果治疗前后血脂有显著变化,改善血TC、TG、LDL-C的总有效率分别为96.8%、71.4%、67%未发现明显不良反应。结论阿托伐他汀治疗高脂血症效果显著,对心脑血管疾病有预防作用。     

Increased hypoglycemia associated with renal failure during continuous intravenous insulin infusion and specialized nutritional support

ObjectiveTo evaluate glycemic control for critically ill, hyperglycemic trauma patients with renal failure who received concurrent intensive insulin therapy and continuous enteral nutrition (EN) or parenteral nutrition (PN).MethodsAdult trauma patients with renal failure who were given EN or PN concurrently with continuous graduated intravenous regular human insulin (RHI) infusion for at least 3 d were evaluated. Our conventional RHI algorithm was modified for those with renal failure by allowing greater changes in blood glucose (BG) concentrations before the infusion rate was escalated. BG concentration was determined every 1 to 2 h while receiving the insulin infusion. BG control was evaluated on the day before RHI infusion and for a maximum of 7 d while receiving RHI. Target BG during the RHI infusion was 70 to 149 mg/dL (3.9 to 8.3 mmol/L). Glycemic control and incidence of hypoglycemia for those with renal failure were compared with a historical cohort of critically ill, hyperglycemic trauma patients without renal failure given our conventional RHI algorithm.ResultsTwenty-one patients with renal failure who received the modified RHI algorithm were evaluated and compared with 40 patients without renal failure given our conventional RHI algorithm. Average BG concentration was significantly greater for those with renal failure (133 ± 14 mg/dL or 7.3 ± 0.7 mmol/L) compared with those without renal failure (122 ± 15 mg/dL or 6.8 ± 0.8 mmol/L), respectively (P < 0.01). Patients with renal failure showed worsened glycemic variability, with 16.1 ± 3.3 h/d within the target BG range, 6.9 ± 3.2 h/d above the target BG range, and 1.4 ± 1.1 h/d below the target BG range compared with 19.6 ± 4.7 h/d (P < 0.001), 3.4 ± 3.0 h/d (P < 0.001), and 0.7 ± 0.8 h/d (P < 0.01) for those without renal failure, respectively. Moderate hypoglycemia (<60 mg/dL or <3.3 mmol/L) occurred in 76% of patients with renal failure compared with 35% without renal failure (P < 0.005). Severe hypoglycemia (BG <40 mg/dL or <2.2 mmol/L) occurred in 29% of patients with renal failure compared with none of those without renal failure (P < 0.001).ConclusionDespite receiving a modified RHI infusion, critically ill trauma patients with renal failure are at greater risk for developing hypoglycemia and have more glycemic variability than patients without renal failure.     

女性绝经状态与血脂代谢的关系研究

目的 通过调查围绝经期和绝经后妇女血脂水平,探讨围绝经和绝经后妇女心血管疾病的防治策略.方法 于2013年4月至2014年12月在上海交通大学附属第六人民医院体检中心健康体检的年龄在40~65岁自然绝经妇女500例,按照生殖衰老分期系统STRAW+10分类分析血脂水平.结果 研究对象的年龄为(53.84±4.86)岁,总胆固醇水平为(5.55±0.97)mmol/L、甘油三酯水平为(1.27±0.80)mmol/L、高密度脂蛋白为(1.63±0.35)mmol/L、低密度脂蛋白水平为(3.45±0.82)mmol/L,其中血脂异常率占38.60%~72.80%.绝经后妇女的总胆固醇(5.69±0.89mmol/L vs 5.47±1.01mmol/L)、甘油三酯(1.38±0.93 mmol/L vs 1.20±0.70mmol/L)及低密度脂蛋白(3.59±0.75mmol/L vs 3.41±0.86mmol/L)均高于围绝经期妇女,且都存在统计学差异(t值分别为6.046、5.804、5.872,均P<0.05).结论 围绝经期和绝经后妇女血脂异常率高,患者干预率低,常规进行血脂检查十分必要.     

孕妇血尿钙镁与骨代谢指标BGP和DPD的相关性临床研究

目的:研究孕妇妊娠期钙、镁及骨代谢指标骨钙素、尿脱氧吡啶酚的变化。方法:240例初孕妇按孕期分为早(16±1)周、中(26±1)周、晚(36±1)周3组,每组80例,60例健康未孕妇女作为对照组。测其空腹静脉血中的钙(Ca2+)、镁(Mg2+)、骨钙素(BGP),同时测其尿Ca2+、Mg2+及尿脱氧吡啶啉(DPD)、肌酐(Cr)。结果:孕妇血清钙浓度由孕早期的(1.840±0.39)mmol/L降至孕末期的(1.710±0.31)mmol/L,明显低于非孕妇(2.375±0.42)mmol/L,P<0.01;血清镁由孕早期的(0.818±0.095)mmol/L降至孕末期的(0.74±0.095)mmol/L,低于非孕妇(1.090±0.53)mmol/L,P<0.05;血清BGP由孕早期的(6.16±3.33)ng/L降至孕晚期的(3.93±2.57)ng/L,均明显低于非孕妇(7.24±4.04)ng/ml,P<0.01。尿Ca2+/Cr在妊娠过程中呈上升趋势,由孕早期的(0.51±0.23)上升至孕晚期的(0.70±0.32),高于非孕妇(0.19±0.13),P<0.05;尿DPD/Cr由孕早期的(17.59±5.65)升至孕晚期的(24.4±14.4),明显高于非孕妇(12.95±2.44),P<0.01。尿Ca2+、Mg2+与DPD正相关(r分别为0.617、0.648,P<0.01),血清Ca2+与DPD呈负相关(r=-0.226,P<0.05)。结论:孕妇体内处于低钙、低镁状态,骨吸收增加,骨骼钙负荷增加。正常膳食不能满足母体及胎儿生长发育的需要,补充维生素D、钙的同时应注意镁的摄取。     

Effects of 12-week supplementation of <Emphasis Type="Italic">Citrus bergamia</Emphasis> extracts-based formulation CitriCholess on cholesterol and body weight in older adults with dyslipidemia: a randomized,double-blind,placebo-controlled trial

Backgrounds

Recent experiments suggest that Citrus bergamia extracts could benefit people with dyslipidemia and obesity but this needs to be further validated.

Methods

A total of 98 people age-matched older adults (65 years) with elevated blood lipids were enrolled to receive 12-week supplementation of a Citrus bergamia extracts-based formulation (CitriCholess)(n?=?48) and placebo (n?=?50).

Results

No group differences were found in baseline bodyweight, body mass index (BMI), blood cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C) and glucose levels. CitriCholess supplementation resulted in lower levels than placebo in TG (1.83?±?0.92 vs. 1.95?±?1.34 mmol/L, P?=?0.612), TC (5.14?±?0.98 vs. 5.44?±?0.77 mmol/L, P?=?0.097), and LDL-C (3.13?±?0.74 vs. 3.43?±?0.62 mmol/L, P?=?0.032). Compared to placebo, CitriCholess also resulted in greater reductions in body weight (?0.604?±?0.939 vs. 0.06?±?0.74 kg, P?<?0.01), waist circumferences (?0.60?±?1.349 cm vs. -0.16?±?1.503 cm, P?<?0.01) and BMI (?0.207?±?0.357 vs. 0.025?±?0.274, P?<?0.01). Additionally, females had a significantly higher level of HDL-C than males. TC was significantly correlated with LDL-C, and to a less degree, with TG. TG was inversely correlated with HDL-C. Body weight and waist circumference were negatively correlated with HDL-C and positively correlated with glucose.

Conclusion

12-week supplementation of CitriCholess could benefit lipid metabolism and weight management in old adults with dyslipidemia.

     

Amino acid supplementation decreases plasma and liver triacylglycerols in elderly

ObjectiveHypertriglyceridemia is a risk factor for coronary heart disease. The aim of this study was to determine the effect of amino acid (AA) supplementation on plasma, liver, and muscle lipid concentrations and insulin sensitivity in the elderly.MethodsTwelve impaired glucose tolerant elderly (mean ± SD 67.0 ± 5.6 y of age, seven women and five men) ingested 11 g of essential AAs plus arginine twice a day for 16 wk, after a 7-wk control run-in. Diet and activity were not otherwise modified. Plasma lipid concentrations and oral glucose tolerance were measured every fourth week and tissue lipid concentrations (magnetic resonance spectroscopy) every eighth week.ResultsNo changes in plasma lipids were observed during the control run-in. AA supplementation lowered plasma triacylglycerol (TG; P < 0.001), total cholesterol (P = 0.048), and very low-density lipoprotein cholesterol (P < 0.001) concentrations. Plasma TG decreased ～20% from the initial value of 1.45 ± 0.18 mmol/L (mean ± SE, 128 ± 16 mg/dL), with the greatest decrease in the subjects starting out with the highest concentrations (r = ?0.83). Similarly, liver fat content (liver TG/Intralipid standard) decreased ～50% from the initial value of 0.34 ± 0.06 (P = 0.021, n = 8), with the greatest decrease in the subjects who initially had the highest values (r = ?0.86). Intramuscular fat content and insulin sensitivity did not change.ConclusionDiet supplementation with AAs lowers plasma TG, total cholesterol, and very low-density lipoprotein cholesterol concentrations and liver lipid content in impaired glucose tolerant elderly. AA supplementation may have a potential role in the treatment of hypertriglyceridemia or hepatic steatosis.